

Supplementary Information for

**Near-infrared Photoimmunotherapy Targeting Cancer-Associated
Fibroblasts in Patient-Derived Xenografts using a Humanized anti-
Fibroblast Activation Protein Antibody**

Authors and affiliations:

Teruki Kobayashi¹, Kazuhiro Noma¹, Seitaro Nishimura¹, Takuya Kato¹, Noriyuki Nishiwaki¹, Toshiaki Ohara^{1,2}, Tomoyoshi Kunitomo¹, Kento Kawasaki¹, Masaaki Akai¹, Satoshi Komoto¹, Hajime Kashima¹, Satoru Kikuchi¹, Hiroshi Tazawa^{1,3}, Yasuhiro Shirakawa^{1,4}, Peter L Choyke⁵, Hisataka Kobayashi⁵, and Toshiyoshi Fujiwara¹

Affiliations:

¹ Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

² Department of Pathology & Experimental Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

³ Center for Gene and Cell Therapy, Okayama University Hospital, Okayama, Japan.

⁴ Department of Surgery, Hiroshima City Hiroshima Citizens Hospital

⁵ Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

*Corresponding author:

Kazuhiro Noma, Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan Phone: +81-86-235-7255; Fax: +81-86-221-8775; E-mail: knoma@md.okayama-u.ac.jp

List of Supplementary Information

Supplementary Table 1. Clinicopathological characteristic of esophageal cancer in 140 patients

Supplementary Table 2. Multivariate analysis for disease free survival and overall survival with esophageal cancer after esophagectomy

Supplementary Table 1. Clinicopathological characteristic of esophageal cancer in 140 patients

Factors	FAP Area Index		p value
	Low	High	
Age (median, range)	67.00 (40-85)	67.00 (44-85)	0.704
Sex			0.046
female	14	5	
male	56	65	
Main Location			0.321
Ce	3	9	
Ut	13	12	
Mt	34	26	
Lt	12	16	
Ae	8	7	
Histlogic factor			0.208
SCC			
well	10	15	
moderate	30	34	
poor	11	13	
Adenocarcinoma	6	3	
Others	13	5	
Tumor depth			<0.01
T1	48	17	
T2-T4	22	53	
Lymph node metastasis			<0.01
-	44	25	
+	26	45	
Neoadjuvant therapy			0.714
-	47	50	
+	23	20	

Mann-Whitney *U* test; FAP, fibroblast activation protein; SCC, squamous cell carcinoma

Supplementary Table 2. Multivariate analysis for disease free survival and overall survival with esophageal cancer after esophagectomy

Factor	Disease Free Survival			Overall Survival		
	H.R.	95% CI	<i>p</i> value	H.R.	95% CI	<i>p</i> value
FAP (Low vs. High)	2.123	1.218-3.702	<0.01	1.789	1.024-3.124	0.041

Adjusted for age, sex, tumor depth, lymph node metastasis and neoadjuvant therapy.

Cox proportional hazard model; H.R., hazard ratio; CI, confidence interval; FAP, fibroblast activation protein.